HZ-S506
/ Hangzhou HeZheng Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 06, 2022
HZ-S506, a selective and orally bioavailable HPK1 degrader, is efficacious as a single agent or in combination with PD-1 antibody
(SITC 2022)
- "Conclusions In summary, HZ-S506 is a potent and selective degrader of HPK1 with good ADME properties and efficacy. These results support further development of HZ-S506 as a single-agent or combinational therapy with the current checkpoint inhibitors."
Combination therapy • Oncology • IL2 • LCP2
1 to 1
Of
1
Go to page
1